PGE2 suppression of innate immunity during mucosal bacterial infection
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Prostaglandin E2 (PGE2) is an important lipid mediator in inflammatory and immune responses during acute and chronic infections. Upon stimulation by various proinflammatory stimuli such as lipopolysaccharide (LPS), interleukin (IL)-1β, and tumor necrosis factor (TNF)-α, PGE2 synthesis is upregulated by the expression of cyclooxygenases. Biologically active PGE2 is then able to signal through four primary receptors to elicit a response. PGE2 is a critical molecule that regulates the activation, maturation, migration, and cytokine secretion of several immune cells, particularly those involved in innate immunity such as macrophages, neutrophils, natural killer cells, and dendritic cells. Both Gram-negative and Gram-positive bacteria can induce PGE2 synthesis to regulate immune responses during bacterial pathogenesis. This review will focus on PGE2 in innate immunity and how bacterial pathogens influence PGE2 production during enteric and pulmonary infections. The conserved ability of many bacterial pathogens to promote PGE2 responses during infection suggests a common signaling mechanism to deter protective pro-inflammatory immune responses. Inhibition of PGE2 production and signaling during infection may represent a therapeutic alternative to treat bacterial infections. Further study of the immunosuppressive effects of PGE2 on innate immunity will lead to a better understanding of potential therapeutic targets within the PGE2 pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostaglandin E2 synthesis and secretion: The role of PGE2 synthases
Park, J. Y., Pillinger, M. H., & Abramson, S. B. (2006) · Clinical Immunology · doi:10.1016/j.clim.2006.01.016 · Cited by 793 · cited 9×
“PGES−/− macrophages are unable to control H37Rv replication and PGES−/− mice demonstrate significantly higher bacterial burdens at 5 weeks post-infection with virulent M. tuberculosis, suggesting that PGE2 is necessary to control M. tuberculosis during the early stage of infection (Chen et al., 2008).”
BackgroundInfluentialMacLeod (2008) · Bristol Research (University of Bristol) · doi:10.4049/jimmunol · Cited by 448
Cloning of cyclooxygenase-1b (putative COX-3) in mouse
Kis, B., Snipes, J. A., Gaspar, T., Lenzser, G., Tulbert, C. D., & Busija, D. W. (2006) · Inflammation Research · doi:10.1007/s00011-006-0083-z · Cited by 41
Cited by
Prostaglandin E 2 as a Regulator of Immunity to Pathogens
Martínez-Colón, G. J., & Moore, B. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.008 · Cited by 109
Biosensor and Lab-on-a-chip Biomarker-identifying Technologies for Oral and Periodontal Diseases
Steigmann, L., Maekawa, S., Sima, C., Travan, S., Wang, C.-W., & Giannobile, W. V. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.588480 · Cited by 77
Moeinabadi-Bidgoli, K., Babajani, A., Yazdanpanah, G., Farhadihosseinabadi, B., Jamshidi, E., Bahrami, S., & Niknejad, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112026 · Cited by 70
Soderholm, A. T., Barnett, T. C., Sweet, M. J., & Walker, M. J. (2018) · Journal of Leukocyte Biology · doi:10.1189/jlb.4mr0617-227rr · Cited by 51
Metadata
- Authors
- Agard, M., Asakrah, S., & Morici, L. A.
- Venue
- Frontiers in Cellular and Infection Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2013
- Volume
- 3
- Pages
- 45-45
- ISSN
- 2235-2988 (ISSN-L)
- OpenAlex
- W2159447128
- Cited by
- 141
- References
- 3
- FWCI
- 6.08
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: PGE2 suppression of innate immunity during mucosal bacterial infection. https://app.cochat.ai/papers/10.3389/fcimb.2013.00045
- The paper
- Agard, M., Asakrah, S., & Morici, L. A. (2013). PGE2 suppression of innate immunity during mucosal bacterial infection. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2013.00045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.